Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 32 (4), 438-45

Primary Sclerosing Cholangitis

Affiliations
Review

Primary Sclerosing Cholangitis

Kate D Williamson et al. Dig Dis.

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease caused by diffuse inflammation and fibrosis that can involve the entire biliary tree. It is a progressive disorder which can ultimately lead to biliary cirrhosis, portal hypertension and hepatic failure. PSC is a complex genetic disorder with male predominance. Environmental predisposing factors include non-smoking. It is closely associated with inflammatory bowel disease (IBD), particularly ulcerative colitis, which occurs in about two thirds of PSC cases. Recent studies have suggested that PSC-IBD is a separate disease entity from IBD alone with distinctive genetic and phenotypic characteristics. Most PSC patients are asymptomatic at presentation; clinical symptoms include fatigue, jaundice, weight loss, right upper quadrant pain and pruritis. Serum biochemical tests indicate cholestasis, and diagnosis is usually established by cholangiography. In symptomatic patients, median survival from presentation to death or liver transplantation is about 12 years. It is a premalignant condition, and the majority of deaths are from malignancy, particularly cholangiocarcinoma or colonic cancer. PSC has no curative treatment. Medical treatment with ursodeoxycholic acid may slow progression of the disease and reduce colonic dysplasia, though trials lack statistical significance. Liver transplantation is the only option in young patients with PSC and advanced liver disease.

Similar articles

See all similar articles

Cited by 12 articles

  • The Role of Stabilin-1 in Lymphocyte Trafficking and Macrophage Scavenging in the Liver Microenvironment.
    Patten DA, Shetty S. Patten DA, et al. Biomolecules. 2019 Jul 16;9(7):283. doi: 10.3390/biom9070283. Biomolecules. 2019. PMID: 31315308 Free PMC article. Review.
  • Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
    Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C. Lynch KD, et al. Clin Gastroenterol Hepatol. 2020 Jan;18(1):179-187.e6. doi: 10.1016/j.cgh.2019.05.013. Epub 2019 May 14. Clin Gastroenterol Hepatol. 2020. PMID: 31100458 Free PMC article.
  • The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Lynch KD, Keshav S, Chapman RW. Lynch KD, et al. Curr Hepatol Rep. 2019;18(1):115-126. doi: 10.1007/s11901-019-00456-2. Epub 2019 Mar 7. Curr Hepatol Rep. 2019. PMID: 31008013 Free PMC article. Review.
  • Clinical guidelines for primary sclerosing cholangitis 2017.
    Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group. Isayama H, et al. J Gastroenterol. 2018 Sep;53(9):1006-1034. doi: 10.1007/s00535-018-1484-9. Epub 2018 Jun 27. J Gastroenterol. 2018. PMID: 29951926
  • Cholangitis: Diagnosis, Treatment and Prognosis.
    Mohammad Alizadeh AH. Mohammad Alizadeh AH. J Clin Transl Hepatol. 2017 Dec 28;5(4):404-413. doi: 10.14218/JCTH.2017.00028. Epub 2017 Sep 7. J Clin Transl Hepatol. 2017. PMID: 29226107 Free PMC article. Review.
See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback